Preimplantation genetic testing for aneuploidy in donor egg recipients does not decrease number of embryo transfers...

Area of Science:

• Reproductive Medicine
• Genetics
• In Vitro Fertilization (IVF)

Background:

• Donor oocyte recipients often undergo in vitro fertilization (IVF) to achieve pregnancy.
• The role of preimplantation genetic testing for aneuploidy (PGT-A) in optimizing outcomes for this population is an area of ongoing research.
• Understanding the impact of PGT-A on efficiency metrics like embryo transfers (ETs) and time to live birth is crucial for patient counseling.

Purpose of the Study:

• To investigate the association between PGT-A use and the number of ETs required to achieve a live birth in donor oocyte recipients.
• To evaluate the impact of PGT-A on the time taken to achieve a live birth from the first ET and from fertilization.
• To assess if PGT-A influences live birth rates or spontaneous abortion rates in this patient group.

Main Methods:

• Retrospective cohort study including donor oocyte recipients undergoing IVF between 2016 and 2024.
• Comparison of outcomes between patients who used PGT-A and those who did not.
• Analysis of primary outcomes (number of ETs to live birth) and secondary outcomes (time to live birth, live birth rate, spontaneous abortion rate) using statistical models.

Main Results:

• No significant difference was found in the number of ETs required to achieve a first live birth between PGT-A users and non-users (HR 0.89, CI 95% [0.73-1.09]).
• Time to live birth, both from first ET (HR 0.93, CI 95% [0.77-1.13]) and from fertilization (HR 1.07, CI 95% [0.83-1.36]), was similar between groups.
• PGT-A use was not associated with a significantly different live birth rate after the first ET (aOR 1.29, CI 95% [0.91-1.84]) or rates of spontaneous abortion.

Conclusions:

• PGT-A use does not appear to impact the efficiency of achieving a live birth in terms of the number of embryo transfers or time to pregnancy for donor oocyte recipients.
• These findings support current counseling practices for donor oocyte recipients regarding the utilization of PGT-A.
• Further research may explore other potential benefits or specific subgroups where PGT-A might offer advantages.